Wikipedia -WSS

Wikipedia

author：knowledge 2025-08-12 06:43:07 - browse：87

A person wears a headset projecting a brain -- health tech coverage from STAT — Adobe

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the neurodegenerative disease.

With the new Series B extension funding, the Cambridge, Mass.-based company has now raised $128 million to develop its headset that uses gamma frequency light and sound stimulation to combat the cognitive decline that’s the hallmark of Alzheimer’s. Cognito is currently undertaking a large study of the treatment and CEO Brent Vaughan told STAT he expects the company to complete the trial and submit data to the Food and Drug Administration for review by the end of 2025.

While under treatment, patients use the device for one hour per day in their homes. The light and sound is supposed to stimulate brain activity that’s disrupted by neurodegenerative conditions, potentially helping to preserve brain structure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

WSS

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Palantir health business leans on meeting customers’ needs

Having children helps parents live longer, especially after age 80

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Artificial intelligence use in health care faces greater scrutiny in 2024

Lecanemab for Alzheimer's is coming. Is the health system ready?

focus

Wikipedia

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

Living with Fabry disease, a condition that causes chronic pain

At least 13 dead in Texas as scorching temps continue

Abbott's new heart device gets FDA advisory panel nod

Supreme Court strikes down use of affirmative action

Elizabeth Holmes on track for early release from her 11

The high cost of giving birth even with insurance

Retired US general questions alleged Putin, Prigozhin meeting

BioMarin wins approval for gene therapy to treat hemophilia A

AMAs digital advisors table RPM coding reform proposal, again

focus

Study: Pain burden is higher in Black NFL players than white ones

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Eli Lilly reports tirzepatide MASH success during Q4 earnings

ACIP vaccine advisory panel sees its vacancies filled

Lecanemab for Alzheimer's is coming. Is the health system ready?

It's time to get medical device identifiers over the finish line

hotspot

focus

focus

focus